A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice

FASEB Journal

Volumn 27, Issue 1, 2013, Pages 174-186

  Shukla, Varsha ^a   Zheng, Ya Li ^c   Mishra, Santosh K ^b   Amin, Niranjana D ^a   Steiner, Joseph ^a   Grant, Philip ^a   Kesavapany, Sashi ^d   Pant, Harish C ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^c Ningxia People's Hospital   (China)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Cdk5 hyperphosphorylation; Neurodegeneration; Therapeutics

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CYCLIN DEPENDENT KINASE 5; NEUROFILAMENT PROTEIN; NOOTROPIC AGENT; PROTEIN P35; SODIUM CHLORIDE; TAU PROTEIN; TFP5 PEPTIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DISEASE MODEL; DRUG PENETRATION; ENZYME INHIBITION; ENZYME REPRESSION; FEMALE; LIFESPAN; MALE; MEMORY DISORDER; MOTOR DYSFUNCTION; MOUSE; NERVE CELL NECROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SINGLE DRUG DOSE; TOXICITY TESTING;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; ENZYME ACTIVATORS; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; NERVE TISSUE PROTEINS; PHOSPHORYLATION;

MUS;

EID: 84871862823     PISSN: None     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.12-217497     Document Type: Article

References (71)

1. Bard, F., Cannon, C., Barbour, R., Burke, R. L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Lieberburg, I., Motter, R., Nguyen, M., Soriano, F., Vasquez, N., Weiss, K., Welch, B., Seubert, P., Schenk, D., and Yednock, T. (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916-919 (Pubitemid 30644751)
2. Maier, M., Seabrook, T. J., Lazo, N. D., Jiang, L., Das, P., Janus, C., and Lemere, C. A. (2006) Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J. Neurosci. 26, 4717-4728 (Pubitemid 44315311)
3. Ritchie, C. W., Ames, D., Clayton, T., and Lai, R. (2004) Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am. J. Geriatr. Psychiat. 12, 358-369 (Pubitemid 38878856)
4. Shukla, V., Mishra, S. K., and Pant, H. C. (2011) Oxidative stress in neurodegeneration. Adv. Pharmacol. Sci. 2011, 572634
5. de la Monte, S. M., Ganju, N., Feroz, N., Luong, T., Banerjee, K., Cannon, J., and Wands, J. R. (2000) Oxygen free radical injury is sufficient to cause some Alzheimer-type molecular abnormalities in human CNS neuronal cells. J. Alzheimers Dis. 2, 261-281 (Pubitemid 32095611)
6. Bonda, D. J., Wang, X., Perry, G., Nunomura, A., Tabaton, M., Zhu, X., and Smith, M. A. (2010) Oxidative stress in Alzheimer disease: a possibility for prevention. Neuropharmacology 59, 290-294
7. Lee, H. P., Zhu, X., Casadesus, G., Castellani, R. J., Nunomura, A., Smith, M. A., Lee, H. G., and Perry, G. (2010) Antioxidant approaches for the treatment of Alzheimer's disease. Expert Rev. Neurother. 10, 1201-1208
8. Patrick, G. N., Zukerberg, L., Nikolic, M., de la Monte, S., Dikkes, P., and Tsai, L. H. (1999) Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402, 615-622 (Pubitemid 129516324)
9. Ahlijanian, M. K., Barrezueta, N. X., Williams, R. D., Jakowski, A., Kowsz, K. P., McCarthy, S., Coskran, T., Carlo, A., Seymour, P. A., Burkhardt, J. E., Nelson, R. B., and McNeish, J. D. (2000) Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc. Natl. Acad. Sci. U. S. A. 97, 2910-2915 (Pubitemid 30159271)
10. Nikolic, M., Dudek, H., Kwon, Y. T., Ramos, Y. F., and Tsai, L. H. (1996) The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation. Genes Dev. 10, 816-825 (Pubitemid 26114738)
11. Ohshima, T., Ward, J. M., Huh, C. G., Longenecker, G., Veeranna, Pant, H. C., Brady, R. O., Martin, L. J., and Kulkarni, A. B. (1996) Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc. Natl. Acad. Sci. U. S. A. 93, 11173-11178 (Pubitemid 26333137)
12. Tan, T. C., Valova, V. A., Malladi, C. S., Graham, M. E., Berven, L. A., Jupp, O. J., Hansra, G., McClure, S. J., Sarcevic, B., Boadle, R. A., Larsen, M. R., Cousin, M. A., and Robinson, P. J. (2003) Cdk5 is essential for synaptic vesicle endocytosis. Nat. Cell Biol. 5, 701-710 (Pubitemid 36986777)
13. Lee, M. S., Kwon, Y. T., Li, M., Peng, J., Friedlander, R. M., and Tsai, L. H. (2000) Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405, 360-364 (Pubitemid 30337070)
14. Noble, W., Olm, V., Takata, K., Casey, E., Mary, O., Meyerson, J., Gaynor, K., LaFrancois, J., Wang, L., Kondo, T., Davies, P., Burns, M., Veeranna, Nixon, R., Dickson, D., Matsuoka, Y., Ahlijanian, M., Lau, L. F., and Duff, K. (2003) Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38, 555-565 (Pubitemid 36645031)
15. Helal, C. J., Sanner, M. A., Cooper, C. B., Gant, T., Adam, M., Lucas, J. C., Kang, Z., Kupchinsky, S., Ahlijanian, M. K., Tate, B., Menniti, F. S., Kelly, K., and Peterson, M. (2004) Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease. Bioorg. Med. Chem. Lett. 14, 5521-5525 (Pubitemid 39346337)
16. Helal, C. J., Kang, Z., Lucas, J. C., Gant, T., Ahlijanian, M. K., Schachter, J. B., Richter, K. E., Cook, J. M., Menniti, F. S., Kelly, K., Mente, S., Pandit, J., and Hosea, N. (2009) Potent and cellularly active 4-aminoimidazole inhibitors of cyclin-dependent kinase 5/p25 for the treatment of Alzheimer's disease. Bioorg. Med. Chem. Lett. 19, 5703-5707
17. Knockaert, M., Wieking, K., Schmitt, S., Leost, M., Grant, K. M., Mottram, J. C., Kunick, C., and Meijer, L. (2002) Intracellular targets of paullones. Identification following affinity purification on immobilized inhibitor. J. Biol. Chem. 277, 25493-25501 (Pubitemid 34951864)
18. Zheng, Y. L., Kesavapany, S., Gravell, M., Hamilton, R. S., Schubert, M., Amin, N., Albers, W., Grant, P., and Pant, H. C. (2005) A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons. EMBO J. 24, 209-220 (Pubitemid 40188478)
19. Zheng, Y. L., Amin, N. D., Hu, Y. F., Rudrabhatla, P., Shukla, V., Kanungo, J., Kesavapany, S., Grant, P., Albers, W., and Pant, H. C. (2010) A 24-residue peptide (p5), derived from p35, the Cdk5 neuronal activator, specifically inhibits Cdk5-p25 hyperactivity and tau hyperphosphorylation. J. Biol. Chem. 285, 34202-34212
20. Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., Berry, R., and Vassar, R. (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129-10140 (Pubitemid 44527407)
21. Zheng, Y. L., Li, B. S., Veeranna, and Pant, H. C. (2003) Phosphorylation of the head domain of neurofilament protein (NF-M): a factor regulating topographic phosphorylation of NF-M tail domain KSP sites in neurons. J. Biol. Chem. 278, 24026-24032
22. Holcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., Sanders, S., Zehr, C., O'Campo, K., Hardy, J., Prada, C. M., Eckman, C., Younkin, S., Hsiao, K., and Duff, K. (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4, 97-100 (Pubitemid 28133087)
23. Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., and Cole, G. (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99-102 (Pubitemid 26332733)
24. Bolognin, S., Blanchard, J., Wang, X., Basurto-Islas, G., Tung, Y. C., Kohlbrenner, E., Grundke-Iqbal, I., and Iqbal, K. (2012) An experimental rat model of sporadic Alzheimer's disease and rescue of cognitive impairment with a neurotrophic peptide. Acta Neuropathol. 123, 133-151
25. Fischer, A., Sananbenesi, F., Pang, P. T., Lu, B., and Tsai, L. H. (2005) Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory. Neuron 48, 825-838 (Pubitemid 41759432)
26. Cyr, M., Beaulieu, J. M., Laakso, A., Sotnikova, T. D., Yao, W. D., Bohn, L. M., Gainetdinov, R. R., and Caron, M. G. (2003) Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc. Natl. Acad. Sci. U. S. A. 100, 11035-11040 (Pubitemid 37140148)
27. Ho, A., Schwarze, S. R., Mermelstein, S. J., Waksman, G., and Dowdy, S. F. (2001) Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer Res. 61, 474-477 (Pubitemid 32128600)
28. Schwarze, S. R., Ho, A., Vocero-Akbani, A., and Dowdy, S. F. (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285, 1569-1572 (Pubitemid 29420581)
29. Royce, J. On the construct validity of open-field measures. Psychol. Bull. 84, 1098-1106
30. Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., and Binder, L. I. (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U. S. A. 83, 4913-4917
31. Kosik, K. S., Joachim, C. L., and Selkoe, D. J. (1986) Microtubule- associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 83, 4044-4048 (Pubitemid 16062419)
32. Lee, V. M., Balin, B. J., Otvos, L., and Trojanowski, J. Q. (1991) A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science 251, 675-678 (Pubitemid 21916893)
33. Uda, K., Masliah, E., Saitoh, T., Bakalis, S. L., Scoble, H., and Kosik, K. S. (1990) Alz-50 recognizes a phosphorylated epitope of tau protein. J. Neurosci. 10, 3295-3304
34. Sternberger, N. H., Sternberger, L. A., and Ulrich, J. (1985) Aberrant neurofilament phosphorylation in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 82, 4274-4276 (Pubitemid 15053626)
35. Cork, L. C., Sternberger, N. H., Sternberger, L. A., Casanova, M. F., Struble, R. G., and Price, D. L. (1986) Phosphorylated neurofilament antigens in neurofibrillary tangles in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 45, 56-64 (Pubitemid 16189843)
36. Rudrabhatla, P., Grant, P., Jaffe, H., Strong, M. J., and Pant, H. C. (2010) Quantitative phosphoproteomic analysis of neuronal intermediate filament proteins (NF-M/H) in Alzheimer's disease by iTRAQ. FASEB J. 24, 4396-4407
37. Rudrabhatla, P., Jaffe, H., and Pant, H. C. (2011) Direct evidence of phosphorylated neuronal intermediate filament proteins in neurofibrillary tangles (NFTs): phosphoproteomics of Alzheimer's NFTs. FASEB J. 25, 3896-3905
38. Lichtenberg-Kraag, B., Mandelkow, E. M., Biernat, J., Steiner, B., Schroter, C., Gustke, N., Meyer, H. E., and Mandelkow, E. (1992) Phosphorylation-dependent epitopes of neurofilament antibodies on tau protein and relationship with Alzheimer tau. Proc. Natl. Acad. Sci. U. S. A. 89, 5384-5388
39. Langley, O. K., Sternberger, N. H., and Sternberger, L. A. (1988) Expression of neurofilament proteins by Purkinje cells: ultrastructural immunolocalization with monoclonal antibodies. Brain Res. 457, 12-20
40. De Strooper, B., and Annaert, W. (2000) Proteolytic processing and cell biological functions of the amyloid precursor protein. J. Cell Sci. 113 (Pt 11), 1857-1870 (Pubitemid 30386490)
41. Lee, M. S., Kao, S. C., Lemere, C. A., Xia, W., Tseng, H. C., Zhou, Y., Neve, R., Ahlijanian, M. K., and Tsai, L. H. (2003) APP processing is regulated by cytoplasmic phosphorylation. J. Cell Biol. 163, 83-95 (Pubitemid 37271436)
42. Cruz, J. C., Tseng, H. C., Goldman, J. A., Shih, H., and Tsai, L. H. (2003) Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40, 471-483 (Pubitemid 37494698)
43. Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G. M., Cooper, N. R., Eikelenboom, P., Emmerling, M., Fiebich, B. L., Finch, C. E., Frautschy, S., Griffin, W. S., Hampel, H., Hull, M., Landreth, G., Lue, L., Mrak, R., Mackenzie, I. R., McGeer, P. L., O'Banion, M. K., Pachter, J., Pasinetti, G., Plata-Salaman, C., Rogers, J., Rydel, R., Shen, Y., Streit, W., Strohmeyer, R., Tooyoma, I., Van Muiswinkel, F. L., Veerhuis, R., Walker, D., Webster, S., Wegrzyniak, B., Wenk, G., and Wyss-Coray, T. (2000) Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383-421 (Pubitemid 30349107)
44. Smith, D. S., and Tsai, L. H. (2002) Cdk5 behind the wheel: a role in trafficking and transport? Trends Cell Biol. 12, 28-36 (Pubitemid 34164154)
45. Dong, X. X., Wang, Y., and Qin, Z. H. (2009) Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol. Sin. 30, 379-387
46. Luque, F. A., and Jaffe, S. L. (2009) The molecular and cellular pathogenesis of dementia of the Alzheimer's type an overview. Int. Rev. Neurobiol. 84, 151-165
47. Martins, I. J., Berger, T., Sharman, M. J., Verdile, G., Fuller, S. J., and Martins, R. N. (2009) Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease. J. Neurochem. 111, 1275-1308
48. Yankner, B. A., Duffy, L. K., and Kirschner, D. A. (1990) Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 250, 279-282
49. Zheng, Y. L., Li, B. S., Amin, N. D., Albers, W., and Pant, H. C. (2002) A peptide derived from cyclin-dependent kinase activator (p35) specifically inhibits Cdk5 activity and phosphorylation of tau protein in transfected cells. Eur. J. Biochem. 269, 4427-4434
50. Smith, W. W., Gorospe, M., and Kusiak, J. W. (2006) Signaling mechanisms underlying Abeta toxicity: potential therapeutic targets for Alzheimer's disease. CNS Neurol. Disord. Drug Targets 5, 355-361
51. Tseng, H. C., Zhou, Y., Shen, Y., and Tsai, L. H. (2002) A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains. FEBS Lett. 523, 58-62 (Pubitemid 34786058)
52. Cruz, J. C., Kim, D., Moy, L. Y., Dobbin, M. M., Sun, X., Bronson, R. T., and Tsai, L. H. (2006) p25/cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid beta in vivo. J. Neurosci. 26, 10536-10541 (Pubitemid 44564604)
53. Maccioni, R. B., Otth, C., Concha, I. I., and Munoz, J. P. (2001) The protein kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimer's pathology. Eur. J. Biochem. 268, 1518-1527 (Pubitemid 32862683)
54. Rockenstein, E., Torrance, M., Mante, M., Adame, A., Paulino, A., Rose, J. B., Crews, L., Moessler, H., and Masliah, E. (2006) Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease. J. Neurosci. Res. 83, 1252-1261 (Pubitemid 43668008)
55. Nath, R., Davis, M., Probert, A. W., Kupina, N. C., Ren, X., Schielke, G. P., and Wang, K. K. (2000) Processing of cdk5 activator p35 to its truncated form (p25) by calpain in acutely injured neuronal cells. Biochem. Biophys. Res. Commun. 274, 16-21 (Pubitemid 30496750)
56. Kurt, M. A., Davies, D. C., Kidd, M., Duff, K., and Howlett, D. R. (2003) Hyperphosphorylated tau and paired helical filamentlike structures in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. Neurobiol. Dis. 14, 89-97 (Pubitemid 37103183)
57. Tsai, L. H., Lee, M. S., and Cruz, J. (2004) Cdk5, a therapeutic target for Alzheimer's disease? Biochim. Biophys. Acta. 1697, 137-142
58. Lopez-Tobon, A., Castro-Alvarez, J. F., Piedrahita, D., Boudreau, R. L., Gallego-Gomez, J. C., and Cardona-Gomez, G. P. (2011) Silencing of CDK5 as potential therapy for Alzheimer's disease. Rev. Neurosci. 22, 143-152
59. Lau, L. F., Seymour, P. A., Sanner, M. A., and Schachter, J. B. (2002) Cdk5 as a drug target for the treatment of Alzheimer's disease. J. Mol. Neurosci. 19, 267-273 (Pubitemid 36051517)
60. Lau, L. F., and Ahlijanian, M. K. (2003) Role of cdk5 in the pathogenesis of Alzheimer's disease. Neurosignals 12, 209-214
61. Monaco, E. A., 3rd, and Vallano, M. L. (2005) Role of protein kinases in neurodegenerative disease: cyclin-dependent kinases in Alzheimer's disease. Front. Biosci. 10, 143-159
62. Lopes, J. P., and Agostinho, P. (2011) Cdk5: multitasking between physiological and pathological conditions. Prog. Neurobiol. 94, 49-63
63. Fischer, A., Sananbenesi, F., Schrick, C., Spiess, J., and Radulovic, J. (2002) Cyclin-dependent kinase 5 is required for associative learning. J. Neurosci. 22, 3700-3707 (Pubitemid 37465775)
64. Wen, Y., Yu, W. H., Maloney, B., Bailey, J., Ma, J., Marie, I., Maurin, T., Wang, L., Figueroa, H., Herman, M., Krishnamurthy, P., Liu, L., Planel, E., Lau, L. F., Lahiri, D. K., and Duff, K. (2008) Transcriptional regulation of beta-secretase by p25/cdk5 leads to enhanced amyloidogenic processing. Neuron 57, 680-690 (Pubitemid 351335351)
65. Giusti-Rodriguez, P., Gao, J., Graff, J., Rei, D., Soda, T., and Tsai, L. H. (2011) Synaptic deficits are rescued in the p25/Cdk5 model of neurodegeneration by the reduction of beta-secretase (BACE1). J. Neurosci. 31, 15751-15756
66. Sadleir, K. R., and Vassar, R. (2012) Cdk5 protein inhibition and Abeta42 increase BACE1 protein level in primary neurons by a post-transcriptional mechanism: implications of CDK5 as a therapeutic target for Alzheimer disease. J. Biol. Chem. 287, 7224-7235
67. Angelo, M., Plattner, F., and Giese, K. P. (2006) Cyclin-dependent kinase 5 in synaptic plasticity, learning and memory. J. Neurochem. 99, 353-370 (Pubitemid 44477194)
68. Hawasli, A. H., and Bibb, J. A. (2007) Alternative roles for Cdk5 in learning and synaptic plasticity. Biotechnol. J. 2, 941-948 (Pubitemid 47377101)
69. Guan, J. S., Su, S. C., Gao, J., Joseph, N., Xie, Z., Zhou, Y., Durak, O., Zhang, L., Zhu, J. J., Clauser, K. R., Carr, S. A., and Tsai, L. H. (2011) Cdk5 is required for memory function and hippocampal plasticity via the cAMP signaling pathway. PLoS One 6, e25735
70. Takahashi, S., Ohshima, T., Hirasawa, M., Pareek, T. K., Bugge, T. H., Morozov, A., Fujieda, K., Brady, R. O., and Kulkarni, A. B. (2010) Conditional deletion of neuronal cyclin-dependent kinase 5 in developing forebrain results in microglial activation and neurodegeneration. Am. J. Pathol. 176, 320-329
71. Kitazawa, M., Oddo, S., Yamasaki, T. R., Green, K. N., and LaFerla, F. M. (2005) Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J. Neurosci. 25, 8843-8853 (Pubitemid 41384452)